ChiCTR2400091031 版本V1.0 版本创建时间2024/10/18 16:20:15 中国临床试验注册中心

审核状态:

Project audit state:

通过审核

Successful

注册号:

Registration number:

ChiCTR2400091031 

最近更新日期:

Date of Last Refreshed on:

2024-10-18 16:20:10 

注册时间:

Date of Registration:

2024-10-18 00:00:00 

注册号状态:

预注册

Registration Status:

Prospective registration

注册题目:

比较不同麻醉深度下舒更葡糖钠对声门变化的影响

Public title:

Change of the glottis following sugammadex administration under different anesthesia depth

注册题目简写:

English Acronym:

研究课题的正式科学名称:

比较不同麻醉深度下舒更葡糖钠对声门变化的影响

Scientific title:

Change of the glottis following sugammadex administration under different anesthesia depth

研究课题代号(代码):

Study subject ID:

在二级注册机构或其它机构的注册号:

The registration number of the Partner Registry or other register:

申请注册联系人:

高令奇 

研究负责人:

王英伟 

Applicant:

Lingqi Gao 

Study leader:

Yingwei Wang 

申请注册联系人电话:

Applicant telephone:

+86 21 5288 7693

研究负责人电话:

Study leader's telephone:

+86 21 5288 7693

申请注册联系人传真 :

Applicant Fax:

研究负责人传真:

Study leader's fax:

申请注册联系人电子邮件:

Applicant E-mail:

aiqi5288@126.com

研究负责人电子邮件:

Study leader's E-mail:

wangyingwei@yahoo.com

申请单位网址(自愿提供):

Applicant website(voluntary supply):

研究负责人网址(自愿提供):

Study leader's website(voluntary supply):

申请注册联系人通讯地址:

上海市乌鲁木齐中路12号

研究负责人通讯地址:

上海市乌鲁木齐中路12号

Applicant address:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China

Study leader's address:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China

申请注册联系人邮政编码:

Applicant postcode:

研究负责人邮政编码:

Study leader's postcode:

申请人所在单位:

复旦大学附属华山医院

Applicant's institution:

Huashan Hospital, Fudan University

研究负责人所在单位:

复旦大学附属华山医院

Affiliation of the Leader:

Huashan Hospital, Fudan University

是否获伦理委员会批准:

是/Yes

Approved by ethic committee:

Yes

伦理委员会批件文号:

Approved No. of ethic committee:

(2024)临审第(1034)号

伦理委员会批件附件:

Approved file of Ethical Committee:

查看附件View

批准本研究的伦理委员会名称:

复旦大学附属华山医院伦理审查委员会(HIRB)

Name of the ethic committee:

Huashan Hospital Institutional Review Board (HIRB), Fudan University

伦理委员会批准日期:

Date of approved by ethic committee:

2024-09-02 00:00:00

伦理委员会联系人:

吴翠云

Contact Name of the ethic committee:

Cuiyun Wu

伦理委员会联系地址:

上海市乌鲁木齐中路12号

Contact Address of the ethic committee:

12 Middle Wulumuqi Road, Jing'an District, Shanghai, China

伦理委员会联系人电话:

Contact phone of the ethic committee:

+86 21 5288 8045

伦理委员会联系人邮箱:

Contact email of the ethic committee:

研究实施负责(组长)单位:

复旦大学附属华山医院

Primary sponsor:

Huashan Hospital, Fudan University

研究实施负责(组长)单位地址:

上海市静安区乌鲁木齐中路12号

Primary sponsor's address:

12 Middle Urumqi Road, Jing'an District, Shanghai, China

试验主办单位(项目批准或申办者):

Secondary sponsor:

国家:

中国

省(直辖市):

上海

市(区县):

Country:

China

Province:

Shanghai

City:

单位(医院):

复旦大学附属华山医院

具体地址:

上海市静安区乌鲁木齐中路12号

Institution
hospital:

Department of Anesthesiology, Huashan Hospital, Fudan University

Address:

12 Middle Urumqi Road, Jing'an District, Shanghai, China

经费或物资来源:

自选课题(自筹)

Source(s) of funding:

Self-supporting project

Target disease:

None

Target disease code:

研究类型:

干预性研究

Study type:

Interventional study

研究所处阶段:

探索性研究/预试验 

Study phase:

0

研究设计:

随机平行对照 

Study design:

Parallel 

研究目的:

比较不同麻醉深度下舒更葡糖钠对声门变化的影响,明确舒更葡糖钠的正确给药时机。  

Objectives of Study:

To compare the effects of sugammadex on glottic changes under different anesthesia depths, and to clarify the correct administration time of sugammadex.

药物成份或治疗方案详述:

 

Description for medicine or protocol of treatment in detail:

 

纳入标准:

(1)择期行全麻手术的患者; (2)年龄18~75岁; (3)体重指数(BMI)< 30 kg/m2; (4)ASA 1~3级,无严重的心、肺、肝、肾等重要脏器合并症; (5)手术时间小于3小时。

Inclusion criteria

(1) Patients undergoing elective surgery, (2) Age: 18 ~ 75 years old (3) Body mass index (BMI) < 30 kg/m2 (4) ASA 1 ~ 3, no serious complications of heart, lung, liver, kidney and other important organs. (5) Predicted surgical duration less than 3 hours.

排除标准:

(1)拒绝入组或术后拒绝提供相关信息的患者; (2)对舒更葡糖钠过敏的患者; (3)气道结构异常(张口受限、小下颌、Mallampati分级大于3级、睡眠呼吸暂停、头颈活动度差); (4)接受过口咽喉以及颈部手术或放疗者; (5)反流误吸高危(食管裂孔疝、胃食管反流病、饱胃); (6)慢性咽喉疼痛不适的患者; 7)哮喘、COPD及其他限制性通气障碍患者。

Exclusion criteria:

(1) Patients who refused to enroll or refused to provide relevant information after surgery (2) Patients who are allergic to sugammadex. (3) Abnormal airway structure (restricted mouse open, micromandible, Mallampati classification > 3, OSAS, reduced extent of cervical movement) (4) Previous surgery or radiotherapy in the mouse, laryngeal or cervix (5) High risk of gastroesophageal reflux (hiatus hernia, gastroesophageal reflux disease, full stomach) (6) Chronic throat ache (7) Asthma, COPD or other restrictive ventilation dysfunction

研究实施时间:

Study execute time:

From 2024-09-04 00:00:00 To 2025-12-31 00:00:00  

征募观察对象时间:

Recruiting time:

From 2024-10-20 00:00:00 To 2025-06-30 00:00:00  

干预措施:

Interventions:

组别:

镇静组

样本量:

39

Group:

Sedation group

Sample size:

干预措施:

舒更葡糖钠给药时将BIS维持在60~80

干预措施代码:

Intervention:

BIS was maintained between 60 and 80 when Sugammadex administration.

Intervention code:

组别:

麻醉组

样本量:

39

Group:

General anesthesia group

Sample size:

干预措施:

舒更葡糖钠给药时将BIS维持在40~60

干预措施代码:

Intervention:

BIS was maintained between 40 and 60 when Sugammadex administration.

Intervention code:

研究实施地点:

Countries of recruitment and research settings:

国家:

中国

省(直辖市):

上海 

市(区县):

 

Country:

China 

Province:

Shanghai 

City:

 

单位(医院):

复旦大学附属华山医院 

单位级别:

三级甲等 

Institution
hospital:

Huashan Hospital, Fudan University

Level of the institution:

Tertiary A

测量指标:

Outcomes:

指标中文名:

声门角

指标类型:

主要指标

Outcome:

vocal cord angle

Type:

Primary indicator

测量时间点:

测量方法:

纤支镜直视下声门观察

Measure time point of outcome:

Measure method:

fibrobronchoscopy

指标中文名:

气道峰压

指标类型:

次要指标

Outcome:

peak inspiratory pressure

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

呼气末二氧化碳水平

指标类型:

次要指标

Outcome:

ETCO2

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

指末氧饱和度

指标类型:

次要指标

Outcome:

SPO2

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

指标中文名:

潮气量

指标类型:

次要指标

Outcome:

Tidal volume

Type:

Secondary indicator

测量时间点:

测量方法:

Measure time point of outcome:

Measure method:

采集人体标本:

Collecting sample(s)
from participants:

标本中文名:

组织:

Sample Name:

none

Tissue:

人体标本去向

其它  

说明

Fate of sample:

0thers  

Note:

征募研究对象情况:

Recruiting status:

尚未开始

Not yet recruiting

年龄范围:

Participant age:

最小 Min age 18 years
最大 Max age 75 years

性别:

男女均可

Gender:

Both

随机方法(请说明由何人用什么方法产生随机序列):

统计学家采用计算机生成的随机数字表进行随机分组

Randomization Procedure (please state who generates the random number sequence and by what method):

Statisticians use computer-generated tables of random numbers for random groupings

是否公开试验完成后的统计结果:

Calculated Results after the Study Completed public access:

公开/Public

盲法:

患者、术后随访者与数据分析者设盲

Blinding:

Patients, staff who follow the patients after surgery and data analyzer were blinded to the grouping

试验完成后的统计结果(上传文件):

Calculated Results after
the Study Completed(upload file):

是否共享原始数据:

IPD sharing

No

共享原始数据的方式(说明:请填入公开原始数据日期和方式,如采用网络平台,需填该网络平台名称和网址):

The way of sharing IPD”(include metadata and protocol, If use web-based public database, please provide the url):

None

数据采集和管理(说明:数据采集和管理由两部分组成,一为病例记录表(Case Record Form, CRF),二为电子采集和管理系统(Electronic Data Capture, EDC),如ResMan即为一种基于互联网的EDC:

数据将由电子采集和管理系统进行采集

Data collection and Management (A standard data collection and management system include a CRF and an electronic data capture:

The data will be collected and managed with an electronic data.

数据与安全监察委员会:

Data and Safety Monitoring Committee:

暂未确定/Not yet

注册人:

Name of Registration:

 2024-10-18 16:20:10